Baird Financial Group
TERN

Baird Financial Group’s Terns Pharmaceuticals TERN Stock Holding History

Baird Financial Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,665
Closed -$37.7K – 1853
2025
Q1 		$37.7K Sell
13,665
-355
-3% -$1.45K ﹤0.01% 1741
2024
Q4 		$77.7K Sell
14,020
-189
-1% -$1.28K ﹤0.01% 1728
2024
Q3 		$119K Buy
+14,209
New +$117K ﹤0.01% 1696

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Baird Financial Group's TERN Position: Q2 2025 in Review

Baird Financial Group sold out of Terns Pharmaceuticals (TERN) in Q2 2025, closing a stake of 13,665 shares — an estimated $37.7K sold.

Baird Financial Group first reported a position in TERN in Q3 2024 and held it in 3 quarters. The position peaked at $119K in Q3 2024. 129 funds tracked by Wall St. Rank hold TERN as of Q2 2025.

  • Baird Financial Group reported no remaining Terns Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Baird Financial Group sold 13,665 Terns Pharmaceuticals shares in Q2 2025, an estimated $37.7K.
  • Baird Financial Group first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Baird Financial Group's Terns Pharmaceuticals position peaked at $119K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2025.

Based on Baird Financial Group's 13F filing for Q2 2025, filed 13 Aug 2025.